Zollinger-Ellison Syndrome Cell Models for Research

Zollinger-Ellison Syndrome (ZES) is a rare neuroendocrine disorder characterized by gastrin-secreting tumors (gastrinomas) that cause severe peptic ulcers and diarrhea. The incidence is estimated at 0.5–2 per million population per year (WHO, 2023). ZES accounts for less than 1% of all peptic ulcer disease cases, but it is the most common functional pancreatic neuroendocrine tumor (pNET).

Gastrinomas are often malignant, with 60–90% being malignant and 25–30% metastatic at diagnosis. The 5-year survival for localized disease is approximately 90%, but for metastatic disease it drops to 40–50% (NCI SEER, 2023). Early diagnosis is challenging due to non-specific symptoms, leading to delayed treatment and poorer outcomes.

Key risk factors include multiple endocrine neoplasia type 1 (MEN1) syndrome, which is present in 20–30% of ZES patients. MEN1 is an autosomal dominant disorder caused by mutations in the MEN1 gene, which encodes menin, a tumor suppressor. Sporadic gastrinomas are more common, but the molecular drivers are less understood.

ZES is an ideal model for studying neuroendocrine tumor biology, hormone secretion, and tumorigenesis. Its rarity and well-defined genetic basis (MEN1 mutations) make it a valuable system for understanding tumor suppressor pathways and hormone-driven cancers.

Public datasets, such as TCGA (The Cancer Genome Atlas) and COSMIC, provide genomic and transcriptomic data for pancreatic neuroendocrine tumors, including gastrinomas. However, the scarcity of patient samples and cell lines limits functional studies. Gene-edited cell models, such as MEN1 knockout or knock-in lines, offer a reproducible and scalable platform to dissect the molecular mechanisms and test novel therapies.

Open questions include the role of MEN1 in tumor initiation, the interaction between gastrin and its receptor (CCK2R), and the mechanisms of metastasis. Gene-edited models can address these questions by enabling precise manipulation of key genes.

The pathogenesis of ZES involves several key pathways:

1. MEN1/Histone Methylation Pathway: The MEN1 gene encodes menin, a scaffold protein that regulates gene transcription via histone methylation. Loss of menin leads to dysregulation of cell cycle and apoptosis.

2. Gastrin/CCK2R Signaling: Gastrin, secreted by gastrinomas, binds to the cholecystokinin-2 receptor (CCK2R) on gastric parietal cells, driving acid secretion and promoting tumor growth via autocrine/paracrine loops.

3. PI3K/AKT/mTOR Pathway: Frequently activated in neuroendocrine tumors, promoting cell survival and proliferation.

4. Wnt/β-catenin Pathway: Aberrant activation contributes to tumorigenesis in a subset of gastrinomas.

Data from TCGA (PanNET cohort) and COSMIC (v98).

Key signaling networks in ZES:

• • PI3K/AKT/mTOR: Activation via loss of PTEN or TSC2, leading to increased cell growth and survival.
• • Wnt/β-catenin: Nuclear accumulation of β-catenin promotes transcription of proliferative genes.
• • Gastrin/CCK2R: Autocrine loop stimulates tumor growth and secretion.
• • Cell Cycle Checkpoints: Loss of menin leads to upregulation of cyclin-dependent kinases (CDKs) and bypass of G1/S arrest.
• • Apoptosis: Dysregulation of BCL-2 family proteins, promoting resistance to cell death.

Organoids derived from patient tumors are increasingly used to preserve tumor heterogeneity and 3D architecture. They allow drug testing and genetic manipulation, but are limited by availability and culture complexity.

• • Patient-Derived Xenografts (PDX): Implantation of patient tumor fragments into immunodeficient mice. They retain tumor characteristics but are time-consuming and costly.
• • Genetically Engineered Mouse Models (GEMM): Conditional knockout of Men1 in pancreatic β-cells or gastrin-producing cells leads to tumor formation. These models recapitulate human disease but have long latency.
• • Induced Models: Use of carcinogens or hormonal stimulation (e.g., hypergastrinemia) to induce gastric neuroendocrine tumors.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise genetic modifications. For ZES, key models include:

• • MEN1 knockout cell lines: Generated by CRISPR-Cas9 in BON-1 or QGP-1 cells to study loss-of-function effects.
• • MEN1 knock-in models: Introduction of specific patient mutations (e.g., R460X) to study genotype-phenotype correlations.
• • Reporter lines: GFP-tagged gastrin or CCK2R to monitor signaling.

These models are commercially available from various suppliers, with sequence verification and quality control. They accelerate research by providing reproducible, isogenic backgrounds for functional studies and drug screening.

Gene-edited cells enable systematic validation of candidate genes identified from genomic studies. For example:

• • MEN1 knockout in BON-1 cells leads to increased proliferation and gastrin secretion, confirming its tumor suppressor role.
• • DAXX knockout models help study chromatin remodeling and telomere maintenance.
• • CRISPR screens can identify synthetic lethal partners of MEN1 loss, revealing novel therapeutic targets.

Isogenic pairs (wild-type vs. MEN1 knockout) are used to screen for compounds that selectively kill MEN1-deficient cells. This approach identifies drugs targeting vulnerabilities induced by the mutation.

Resistance to somatostatin analogs (e.g., octreotide) is a clinical challenge. Gene-edited models can be used to study resistance mechanisms by exposing cells to increasing drug concentrations and identifying genetic changes.

CRISPR-based screens can identify genes whose loss sensitizes cells to specific treatments, serving as biomarkers for patient stratification. For example, loss of PTEN may predict response to mTOR inhibitors. Gene-edited models allow validation of these biomarkers in vitro.